{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037610","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2026-08-13T13:00:44+00:00","discovered_at":"2026-08-13T13:02:00.294027+00:00","generated_at":"2026-08-13T13:02:09.227176+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biofrontera Q2 revenue up 33% to $12.0M; net loss narrows to $0.6M","bullets":["Q2 net product revenue $12.0M, up 32.9% YoY; gross margin 80% vs 71% prior year.","Net loss narrowed to $0.6M ($0.05/share) from $5.3M ($0.57/share); Adjusted EBITDA $(0.2)M vs $(5.1)M.","H1 revenue $22.1M (+25.4%); operating cash use cut 76% to $1.7M; cash $4.7M at June 30.","ITC exclusion order on RhodoLED XL lamp effective July 7, 2026; remediation plan underway, full-year revenue goals unchanged.","PDUFA date late September 2026 for sBCC indication; launch expected Q1 2027 if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037610","json":"https://secwatch.observer/filing/0001493152-26-037610.json","markdown":"https://secwatch.observer/filing/0001493152-26-037610.md","text":"https://secwatch.observer/filing/0001493152-26-037610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226037610/0001493152-26-037610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226037610/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T13:02:09.227176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}